REVOLUTION Medicines Revenue and Competitors

Location

$486.9M

Total Funding

Biotech

Industry

Estimated Revenue & Valuation

  • REVOLUTION Medicines's estimated annual revenue is currently $81.6M per year.(i)
  • REVOLUTION Medicines received $56.0M in venture funding in April 2018.
  • REVOLUTION Medicines's estimated revenue per employee is $217,000
  • REVOLUTION Medicines's total funding is $486.9M.

Employee Data

  • REVOLUTION Medicines has 376 Employees.(i)
  • REVOLUTION Medicines grew their employee count by 28% last year.
Competitor NameRevenueNumber of EmployeesEmployee GrowthTotal FundingValuation
#1
$4.4M57-8%$53MN/A
#2
$21.2M137-26%$110MN/A
#3
$1.1M70%N/AN/A
#4
$2.3M15150%N/AN/A
#5
$1.4M90%N/AN/A
#6
$11.5M74-12%N/AN/A
#7
$0.4M27510%$236.7MN/A
#8
$4M51-74%$160MN/A
#9
$2.5M1633%N/AN/A
#10
$3.3M21-12%N/AN/A
Add Company

REVOLUTION Medicines discovers and develops new drugs that harness the therapeutic potential of frontier oncology targets on behalf of cancer patients. Our innovative product engine draws inspiration from nature and evolution, which offer insights into cancer targets, disease mechanisms and therapeutic approaches. We pay particular attention to natural products that are inherently rich with biological function as a result of natural selection and can inform and guide our discovery and development of small molecules that can modulate these targets.

keywords:Biotechnology,Healthcare,Pharmaceuticals

$486.9M

Total Funding

376

Number of Employees

$81.6M

Revenue (est)

28%

Employee Growth %

N/A

Valuation

N/A

Accelerator

REVOLUTION Medicines News

2022-04-17 - Revolution Medicines (NASDAQ:RVMD) Rating Increased to ...

Revolution Medicines (NASDAQ:RVMD) Rating Increased to Hold at Zacks Investment Research. Posted by admin on Apr 16th, 2022.

2022-04-17 - Revolution Medicines : RMC-9805 (RM-036), a First-in-Class, Orally-Bioavailable, Tri-Complex Covalent KRAS-G12D(ON) Inhibitor, Drives Profound Anti-Tumor Activity in KRAS-G12D Mutant Tumor Models

Revolution Medicines : RMC-9805 (RM-036), a First-in-Class, Orally-Bioavailable, Tri-Complex Covalent KRAS-G12D(ON) Inhibitor, Drives Profound...

2022-04-06 - How Does Revolution Medicines Inc (RVMD) Stock Rank on Wall Street Tuesday?

Wall Street is positive on Revolution Medicines Inc (RVMD). On average, analysts give RVMD a Strong Buy rating. The average price target is...

2019-09-09 - Lilly launches new report highlighting challenges and ...

... highlighting challenges and opportunities of health care revolution ... its global leadership position at the forefront of medicines research and ...

2019-09-08 - Amgen's drug targeting 'undruggable' protein shines at lung ...

In June, Frontier Medicines launched with a $67 million Series A ... And in July, Revolution Medicines raised a $100 million equity round for its ...

Company NameRevenueNumber of EmployeesEmployee GrowthTotal Funding
#1
$34M3824%$17.5M
#2
$50M400N/AN/A
#3
$67.5M409-1%$204.5M
#4
$300M4421%N/A
#5
$83.4M4690%$61.1M

REVOLUTION Medicines Funding

DateAmountRoundLead InvestorsReference
2015-02-05$45.0MAThird Rock Ventures, LLCArticle
2016-12-21$25.0MAThe Column GroupArticle
2018-04-25$56.0MBNextech InvestArticle

REVOLUTION Medicines Executives


NameTitle
Mark GoldsmithPresident & CEO
Mark GoldsmithCEO and President
Peg HornChief Operating Officer
Tammy FischettiExecutive Assistant to the CEO
Wally ReiherVP Information Services
XIAOLIN wangSVP, Clinical Development
Mark GoldsmithPresident & CEO
Jack AndersVP, Finance & Principal, Accounting Officer
Luan WilfongSenior Vice President Human Resources
Elena KoltunVP, Medicinal Chemistry
Jason LindowVice President, Clinical Operations
Mark GoldsmithCEO and President
Shaoling LiSr. Vice President, CMC and Quality
Tamara KaleVice President, Associate General Counsel, Intellectual Property
Steve KelseyPresident
Jan SmithSenior Vice President, Head of Biology
Jeff CisliniSVP, General Counsel and Corporate Secretary
Marieke VanVP Program, Portfolio, and Alliance Management
David ArringtonSenior Vice President Investor Relations & Corporate Affairs
Xiaolin WangEVP Clinical Development